Aquarius were part of a recent feasibility trial looking at whether provision of a same day test and treatment service for chlamydia in further education colleges increased uptake of chlamydia testing and treatment. The results of the trial were published this week in Clinical Microbiology and Infection and are available online.
An article authored by Aquarius was published today on the British In Vitro Diagnostics Association (BIVDA) website. The article commissioned jointly by BIVDA and Innovate UK suggests that the NHS could save over £6.9 billion in 5 years by making better use of diagnostic tests already on the market. These savings could have a huge impact in reducing the annual NHS shortfall, which is expected to be £20 billion by 2022.
The winter flu season brings added pressure to emergency and acute hospital services. In the UK, children and infants account for more than a third of flu related hospital admissions since flu and respiratory syncytial viruses (RSV) can be particularly severe in children, particularly those with existing conditions such as asthma.
In our recent paper published, we report the results of a real-world evaluation conducted in a busy children’s hospital in central London. We assessed the impact and economic benefits of using a 90-minute point-of-care (POC) assay to test for influenza and RSV in children and infants admitted to hospital. This was done by comparing data collected from an acute paediatric ward during one flu season, when standard laboratory testing was used, with data collected from the same ward in the subsequent flu season, when the POC test was in use.
Work has begun to develop a digital value proposition tool for a novel rapid sexually transmitted infection (STI) test
London, UK, 14 August 2017
Aquarius Population Health, a leading independent health economics consultancy, has recently been awarded an 18-month Innovate UK grant in collaboration with Atlas Genetics Ltd and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London (total £2,000,000). The funding will be used to develop evidence for health services to support the introduction of a new rapid diagnostic test. In 30-minutes the test can diagnose multiple sexually transmitted infections including chlamydia and gonorrhoea – infections which could take up to a week to diagnose using the current laboratory testing systems.
Aquarius Population Health recently worked with the Applied Diagnostic Research & Evaluation Unit (ADREU) at St. Georges, University of London, to assess the cost-effectiveness of six hypothetical strategies for using antimicrobial resistance point-of-care testing to guide the treatment of gonorrhoea. Our findings were presented at the STI & HIV World Congress in Rio de Janeiro, Brazil. [Wednesday 12th July, Session 15: STI/HIV testing and management].
We were a collaborator on a recent Innovate UK-funded SBRI project with Atlas Genetics and the Applied Diagnostic Research and Evaluation Unit at St George’s University of London. In this project, our team compared the overall costs, patient benefits and cost-effectiveness of three different multi-pathogen point-of-care testing strategies with the current strategy of microscopy and lab-based testing.
In a study commissioned by the Review on Antimicrobial Resistance, Aquarius Population Health worked with modellers at the University of Bristol to create a mathematical model. The model was used to assess the economic implications and treatment impact of introducing a hypothetical antimicrobial resistance (AMR) point-of-care test (POCT) for gonorrhoea. Results of the study were published this week in BMJ Open.
Antimicrobial resistance (AMR) has been described as one of the world’s greatest threats to human and animal health. Some reports suggest that by 2050, AMR could kill around 10 million people each year worldwide. Public health leaders warn we could enter a ‘post-antibiotic’ era where easily treatable common infections become untreatable.
Our Managing Director, Elisabeth Adams, spoke in November about the importance of exploring the health economics of point of care testing (POCT) at the Royal Society of Medicine Telemedicine and eHealth event in London.
Why is it important to explore the health economics of point of care testing (POCT)?
Evaluating the health economics of POCTs can help us better understand the cost, benefits and value of implementing these tests, compared to standard laboratory tests. We need to explore the acquisition costs of innovative technology like POCTs compared to standard tests, as well as the benefits generated for patients, service providers, clinicians and public health in general. Benefits can include faster results, better care, fewer complications, more efficient services and better use of resources, and knock-on benefits like reduced prevalence of disease. Those making purchasing decisions for new tests need evidence to prove the value of the tests.
The team at Aquarius Population Health investigated the experience of implementing point-of-care tests (POCTs) for paediatric patients during respiratory disease season (winter 2014 – spring 2015), in collaboration with colleagues from three large hospitals in South London (Guy’s and St. Thomas’, King’s College Hospital, and St. George’s University Hospital). Each centre independently evaluated one POCT test (Enigma® MiniLab™ FluAB-RSV PCR assay, BioMérieux BioFire Filmarray, and Luminex RVP Fast v2) on paediatric patients either in the Accident and Emergency department or admitted as an inpatient.